Cancer Immunotherapy Meets Oncology In Honor of Christoph Huber /

This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and reg...

Full description

Corporate Author: SpringerLink (Online service)
Other Authors: Britten, Cedrik Michael. (Editor, http://id.loc.gov/vocabulary/relators/edt), Kreiter, Sebastian. (Editor, http://id.loc.gov/vocabulary/relators/edt), Diken, Mustafa. (Editor, http://id.loc.gov/vocabulary/relators/edt), Rammensee, Hans-Georg. (Editor, http://id.loc.gov/vocabulary/relators/edt)
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2014.
Edition:1st ed. 2014.
Subjects:
Online Access:https://doi.org/10.1007/978-3-319-05104-8
Table of Contents:
  • Immunological and Regulatory Framework for Immuno-Oncology: From Basic Immunology to New Therapies for Patients
  • How T cells single out tumor cells: 'and that has made all the difference'
  • Tregs and Immune Inhibition
  • Regulatory Landscape for Cancer Immunotherapy
  • Immunoguiding
  • Onco-Immunology Framework and Immunomodulatory Antibodies
  • Immunotherapies: Peptide-based Vaccines and HPV Malignancies.- Dendritic cell based cancer vaccines.- RNA Vaccines and Personalized Medicine Approaches.-Antibody Therapy in Oncology.- Engineered Antibodies to Engage Immune Cells to the Tumor
  • TCRs and TCR Therapy
  • CAR Therapy.- Cancer Entities: Melanoma
  • Prostate Cancer/Sipuleucel and RNA Vaccines
  • Recent advances in the immunotherapy of renal cell cancer and other solid tumors
  • Gastric Cancer
  • NSCLC
  • Breaking tolerance by allogeneic lymphocyte therapy.- Biomarkers: Exploring Immunogenic Cell Death for Patient Benefit
  • Circulating Tumor Cells
  • Genomics Meets Oncology
  • Featured Chapters: Oncolytic Viruses
  • Pharma View on Immunotherapy
  • Final Remarks.